Company / Operating Cash Flow
IOVANCE BIOTHERAPEUTICS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$302.4M
FY2025
5-year range
-$361.8M / -$227.9M
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#193 of 216
Health Care
What the data says
IOVANCE BIOTHERAPEUTICS, INC.'s operating cash flow of -$302M is lower than 89% of companies in the Health Care sector (FY2025). Improved from -$362M to -$302M over the past 2 years.
Based on SEC 10-K filings.
-$302M in FY2025.
Improved from -$362M to -$302M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 216This company -$302.4M Sector average $659.0M
▼
-145.9% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 14.3% year-over-year.
- Ranks #193 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$302.4M | +14.3% |
| FY2024 | -$353.0M | +2.4% |
| FY2023 | -$361.8M | -23.6% |
| FY2022 | -$292.8M | -28.4% |
| FY2021 | -$227.9M | -11.1% |
| FY2020 | -$205.1M | -29.1% |
| FY2019 | -$158.9M | -56.9% |
| FY2018 | -$101.2M | -28.6% |
| FY2017 | -$78.7M | -811.7% |
| FY2016 | -$8.6M | -135.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026